$19.45
0.593.13%
Last update: Nov 3, 5:36 PM
Denali Therapeutics Inc
DNLINASDAQ
Denali Therapeutics (DNLI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Denali Therapeutics (DNLI) last issued guidance on November 3, 2026 for Q4 2026. The company guided revenue in the range of $30M - $32M for the period.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.43 | $-0.57 | $-0.71 | $-0.75 |
| Actual | $-0.64 | $-0.68 | $-0.69 | $-0.73 |
| Surprise | -48.8% | -19.3% | +2.82% | +2.67% |
| Revenue | ||||
| Estimate | $20.8M | $2.0M | $3.8M | $9.0M |
| Actual | $17.8M | $3.6M | $0 | $0 |
| Surprise | -14.6% | +77.2% | -100.0% | -100.0% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.63 | $-0.58 | $-0.61 | $-0.63 |
| Revenue | ||||
| Consensus | $24.8M | — | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $-0.64 | $-0.43 | -48.8 % |
| Q2 | Aug 6, 2026 | $-0.68 | $-0.57 | -19.3 % |
| Q1 | May 7, 2026 | $-0.69 | $-0.71 | 2.82 % |
| Q4 | Feb 26, 2026 | $-0.73 | $-0.75 | 2.67 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $17.78M | $20.83M | -14.6 % |
| Q2 | Aug 6, 2026 | $3.60M | $2.03M | 77.2 % |
| Q1 | May 7, 2026 | $0 | $3.82M | -100.0 % |
| Q4 | Feb 26, 2026 | $0 | $8.99M | -100.0 % |
